title: Anchorage on fibronectin via VLA-5 (alpha5beta1 integrin) protects rheumatoid synovial cells from Fas-induced apoptosis.
abstract: BACKGROUND
  Rheumatoid synovial cells are resistant to apoptosis induction in vivo, whereas, fibroblast-like synovial cells in rheumatoid arthritis (RA-FLS) are vulnerable to Fas-induced apoptosis in vitro.
  
  
  OBJECTIVE
  To clarify this discrepancy by studying the contribution of the interaction between cellular integrin and matrix fibronectin (Fn), which is significantly increased in the rheumatoid joints, to the induction of apoptosis in RA-FLS.
  
  
  METHODS
  Integrin and Fas mRNAs were measured by reverse transcription-polymerase chain reaction in RA-FLS. Integrins expressed in rheumatoid synovial tissues were analysed by immunohistochemistry. RA-FLS plated either on Fn or on control poly-L-lysine were incubated with agonistic anti-Fas monoclonal antibodies (mAbs). Apoptosis induction was evaluated using terminal deoxynucleotidyl transferase mediated UTP nick end labelling (TUNEL) and immunoblotting for caspase-3 and poly (ADP-ribose) polymerase in the presence or absence of anti-VLA-5 mAb.
  
  
  RESULTS
  VLA-5 (alpha5beta1 integrin), a major integrin expressed on RA-FLS, was required for the adhesion of RA-FLS on Fn. RA-FLS plated on Fn were more resistant to Fas-induced apoptosis than those plated on control poly-L-lysine. This protection by Fn was reversed by anti-VLA-5 mAb.
  
  
  CONCLUSIONS
  Anchorage of RA-FLS on matrix Fn via VLA-5 protects RA-FLS from Fas-induced apoptosis, and Fn abundantly present in rheumatoid synovium appears to afford RA-FLS resistance against apoptosis induction in vivo.
authors.affiliation: Department of Orthopaedic Surgery, Kobe University School of Medicine, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Kitagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Miura
authors.forename: R
authors.initials: R
authors.lastname: Saura
authors.forename: M
authors.initials: M
authors.lastname: Mitani
authors.forename: H
authors.initials: H
authors.lastname: Ishikawa
authors.forename: A
authors.initials: A
authors.lastname: Hashiramoto
authors.forename: S
authors.initials: S
authors.lastname: Yoshiya
authors.forename: S
authors.initials: S
authors.lastname: Shiozawa
authors.forename: M
authors.initials: M
authors.lastname: Kurosaka
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D017209:Apoptosis / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000378:metabolism* / Q000473:pathology; D015415:Biomarkers / Q000032:analysis; D053148:Caspase 3; D020169:Caspases / Q000032:analysis; D002448:Cell Adhesion; D002478:Cells, Cultured; D024161:Collagen Type XI / Q000032:analysis; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology; D005353:Fibronectins / Q000378:metabolism*; D006801:Humans; D015151:Immunoblotting / Q000379:methods; D007150:Immunohistochemistry / Q000379:methods; D020287:In Situ Nick-End Labeling; D039081:Integrin alpha5beta1 / Q000276:immunology / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018709:Statistics, Nonparametric; D013583:Synovial Membrane / Q000378:metabolism* / Q000473:pathology; D019014:fas Receptor / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D015415:Biomarkers; C499319:COL11A2 protein, human; D024161:Collagen Type XI; D005353:Fibronectins; D039081:Integrin alpha5beta1; D019014:fas Receptor; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases